Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
In Vivo Ready™ Anti-Mouse CD279 (PD-1) (J43.1) Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC, FC, IP, FA |
|---|---|
| Isotype | Armenian Hamster IgG |
| Concentration | 2.0 mg/mL |
| Reactivity | Mouse |
| Formulation | 10 mM NaH2PO4, 150 mM NaCl, pH7.2 |
| Gene ID | 18566 |
|---|---|
| Gene Name | Pdcd1 |
| Alternative Name(s) | PDCD1, PD1, SLEB2 |
| Format | In Vivo Ready™ |
| Storage Conditions | 2-8°C |
Provided below are standard protocols that you may find useful for product applications.
Background
The J43.1 antibody is specific for mouse CD279, also known as programmed death-1 (PD-1), a 55 kDa glycoprotein which can co-regulate T cell antigen receptor signaling and therefore modulate T cell activation. PD-1 exists in a monomeric form that is expressed by CD4- CD8- thymocytes, where it participates in the processes of clonal selection, elimination of autoreactive lymphocytes, and development of tolerance. PD-1 expression is also inducible upon activation of mature T cells, where it has been proposed to interact with the co-stimulatory receptor CD80 to limit T cell activation. Two ligands for PD-1, known as PD-L1 (B7-H1) and PD-L2 (B7-DC) are differentially expressed on T and B cells, monocytes, macrophages, NK cells or dendritic cells. PD-1 is a member of a family of receptors including CD28 and CTLA-4 (CD152), which interact with “B7” ligands to provide a balance of co-stimulatory /co-inhibitory signaling important in T cell activation, tolerance, and autoimmunity. The J43.1 antibody may be used as a marker for PD-1 expression, and is commonly used for analysis of receptor-ligand interaction and function(s) in vitro and in vivo. Please choose the appropriate format for each application.
References
Hams E, McCarron MJ, Amu S, Yagita H, Azuma M, Chen L, and Fallon PG. 2011. J. Immunol. 186:5648-5655. (in vivo blocking)
Rivas MN, Weatherly K, Hazzan M, Vokaer B, Dremier S, Gaudray F, Goldman M, Salmon I, and Braun MY. 2009. 183:4284-4291. (in vitro blocking)
Koehn BH, Ford ML, Ferrer IR, Borom K, Gangappa S, Kirk AD, and Larsen CP. 2008. J. Immunol. 181:5313-5322. (in vivo blocking)
Brooks DG, Ha S-J, Elsaesser H, Sharpe AH, Freeman GJ, and Oldstone MBA. 2008. Proc. Natl. Acad. Sci. 105:20428-20433. (Flow cytometry)
Ansari MJI, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Isai H, Khoury SJ, Auchincloss H, and Sayegh MH. 2003. J. Exp. Med. 198:63-71. (Immunohistochemistry – frozen tissue, in vivo blocking)
Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubat T, Yagita H, and Honjo T. 1996. Int. Immunol. 8:765-772. (Immunoprecipitation)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
